For more information regarding these studies, contact Cancer Research & Registry at (601) 984-1095.
BMS CA204-008: PROSPECTIVE RESEARCH ASSESSMENT IN MULTIPLE MYELOMA: AN OBSERVATIONAL EVALUATION (PREAMBLE)
BMS wants to collect information about patients who have multiple myeloma and are receiving any line therapy (including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, histone deacetylase inhibitors, Akt inhibitors, or new drugs) either alone, or in combination as part of their treatment. To collect this information, BMS has created a research database (a database is a way of collecting and keeping information to be used for analysis with the patients enrolled).
Principal Investigator: Carter Milner, MD